. 2019 Sep 3;11(9):458. doi: 10.3390/pharmaceutics11090458

Table 3.

Treatment groups used for in vivo study.

Group	Regimen
Untreated	-
CA	7 µL of 1 M CaCl₂ in DMEM
CA	4 µL of 1 M CaCl₂ in DMEM
Pac	1.25 mg/kg paclitaxel in DMEM
Doc	1 mg/kg docetaxel in DMEM
CA/Pac	1.25 mg/kg paclitaxel and 7 µL of 1 M CaCl₂ in DMEM
CA/Pac	1.25 mg/kg paclitaxel and 4 µL of 1 M CaCl₂ in DMEM
CA/Doc	1 mg/kg docetaxel and 4 µL of 1 M CaCl₂ in DMEM
CA/AKT	50 nM of AKT siRNA and 4 µL of 1 M CaCl₂ in DMEM
CA/ERBB2	50 nM of ERBB2 siRNA and 4 µL of 1 M CaCl₂ in DMEM
CA/AKT/ERBB2/Pac	1.25 mg/kg paclitaxel and 50 nM of ERBB2 and AKT siRNA and 4 µL of 1 M CaCl₂ in DMEM
CA/AKT/ERBB2/Doc	1 mg/kg docetaxel and 50 nM of ERBB2 and AKT siRNA and 4 µL of 1 M CaCl₂ in DMEM